Onur Okan Demirci, Nurhan FISTIKÇI, Eser SAĞALTICI, NESRİN KARAMUSTAFALIOĞLU, ABDULLAH YILDIRIM, Mehmet Cem İLNEM

Metabolic parameters in patients with major depression treated with escitalopram

Amaç: Bu çalışmanın amacı, essitalopram ile tedavi edilen majör depresyon hastalarında metabolik parametrelerin değişimini incelemektir. Yöntem: Essitalopram ile tedavisine karar verilmiş olan, ardışık olarak çalışmaya alınan 41 majör depresyon hastasında tedavi başlanmadan hemen önce ve tedavinin üçüncü ayında boy, vücut ağırlığı, bel çevresi, kan basıncı, lipit profili (total kolesterol, düşük yoğunluklu lipoprotein [LDL], yüksek yoğunluklu lipoprotein [HDL], trigliserit [TG]), açlık kan şekeri, tiroit uyarıcı hormon (TSH) ve Hamilton Depresyon Ölçeği (HamD) ölçümleri yapıldı. On iki hafta sonra tedavi ile metabolik parametreler arasındaki ilişki ve değişimler değerlendirildi. Bulgular: Hastaların ortalama yaşı 30.24±9.96 idi. Hastaların 11'i (%27) erkek, 30'u (%73) kadındı. Hastalardan 12'si (%29.3) 10 mg/gün essitalopram ile, 29'u (%70.7) 20 mg/gün essitalopram ile tedavi edildi. On iki haftalık süreç sonunda beden ağırlığında, vücut kitle indeksinde, bel çevresinde ve sistolik kan basıncında anlamlı artış saptandı. Bu sürenin sonunda, erkek hastalarda (s=11) bel çevresinde anlamlı artış saptandı. Kadın hastalarda (s=30) ise vücut ağırlığında, vücut kitle indeksinde, bel çevresinde, trigliserit düzeylerinde ve sistolik kan basıncında anlamlı artış saptandı. Hastaların HamD puanlarında ise 12 haftanın sonunda anlamlı azalma saptandı. Sonuç: Majör depresyon hastalarında essitalopram kullanımı özellikle beden ağrılığında ve bel çevresinde artışa neden olmuştur.

Essitalopram ile tedavi edilen majör depresyon hastalarında metabolik parametreler

Objective: The aim of this study is to determine the change in metabolic parameters of patients with major depression treated with escitalopram. Methods: The height, body weight, waist circumference, blood pressure, lipid profile (total cholesterol, low density lipoprotein [LDL], high density lipoprotein [HDL], triglycerides [TG]), fasting blood glucose (FBG), thyroid stimulating hormone (TSH) and Hamilton Depression Scale (HamD) of 41 consecutively selected patients with major depression were measured before treatment and in the third month of treatment, for whom a decision to start treatment with escitalopram was decided. The relationship between treatment and changes in these metabolic parameters were evaluated at the end of this period. Results: The mean age of patients was 30.24±9.96 years. Eleven (27%) patients were male and 30 (73%) were female. Twelve (29.3%) patients were treated with 10 mg/day escitalopram, and 29 patients (70.7%) 20 mg/day. Significant increases were detected in body weight, body mass index, waist circumference and systolic blood pressures of all patients from initiation of treatment to three months. A significant increase was found in the waist circumference of male patients (n=11) after three months of treatment. Body weight, body mass index, waist circumference, triglycerides, systolic blood pressure were found to be significantly increased after three months of treatment in female patients (n=30) who were treated with escitalopram. HamD scores were found to be significantly decreased after three months in patients treated with escitalopram. Conclusion: Escitalopram caused an increase in especially body weight and waist circumference in patients with major depression.

PDF

___

Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmacher T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003; 37:193-220.
Himmerich H, Schuld A, Haack M, Kaufmann C, Pollmacher T. Early prediction of changes in weight during six weeks of treatment with antide- pressants. J Psychiatr Res 2004; 38:485-489.
Stahl, SM. Stahl's Essential Psychopharmaco- logy: Neuroscientific Basis and Practical Applica- tions. Cambridge University Press, 2013.
Reader MB, Bjelland I, Emil Vollset S, Steen VM. Obesity dyslipidemia and diabetes with selective serotonin reuptake inhibitors: the Hordaland health. J Clin Psychiatry 2006; 67:1974-1982.
Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-ana- lysis. J Clin Psychiatry 2010; 71:1259-1272.
Ye Z, Chen L, Yang Z, Li Q, Huang Y, He M, et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: A meta-analysis of rando- mized placebo-controlled trials. Plos One 2011; 6:e21551.
Beyazyüz M, Albayrak Y, Eğilmez OB, Albayrak N, Beyazyüz, E. Relationship between SSRIs and metabolic syndrome abnormalities in patients with generalized anxiety disorder: a prospective study. Psychiatry Investig 2013; 10(Suppl.2):148-154.
Peh ALH, Nieng CH, Ling YH, Kheng TW, Neng TS, Koon OG. The effect of escitalopram on meta- bolic parameters in patients with major depressive disorder, generalised anxiety disorder and panic disorder: a prospective 6-month follow-up study. Asian J Psychiatr 2013; 6(Suppl.3):256-257.
Vogelzangs N, Beekman AT, van Reedt Dortland AK, Schoevers RA, Giltay EJ, de Jonge P, et al. Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antide- pressant users. Neuropsychopharmacology 2014; 39(Suppl.7):1624-1634.
First, Michael B. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version. American Psychiatric Pub., 1997.
Çorapçıoğlu, A. DSM-IV Eksen I bozuklukları için yapılandırılmış klinik görüşmenin Türkçeye uyar- lanması ve güvenilirlik çalışması. İlaç ve Tedavi Dergisi 1999; 12(4):33-36.
Akdemir A, Örsel S, Dağ İ, Türkçapar H, İşcan H, Özbay H. Hamilton depresyon derecelendirme ölçeğinin geçerliği, güvenilirliği ve klinikte kullanı- mı. 3P Dergisi 1996; 4:251-256.
Kivimäki M, Hamer M, Batty GD, Geddes JR, Tabak AG, Pentti J, et al. Antidepressant medica- tion use, weight gain, and risk of type 2 diabetes: a population based study. Diabetes Care 2010; 33(Suppl.12):2611-2616.
Price DW, Ma Y, Rubin RR, Perreault L, Bray GA, Marrero D, et al. Depression as a predictor of weight regain among successful weight losers in the diabetes prevention program. Diabetes Care 2013; 36(Suppl.2):216-221.
Hamer M, Batty GD, Seldenrijk A, Kivimaki M. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Sur- vey. Eur Heart J 2011; 32(Suppl.4):437-442.
Uher R, Mors O, Hauser J, Rietschel M, Maier W, Kozel D, et al. Changes in body weight during pharmacological treatment of depression. Int J Neuropsychopharmacol 2011; 14(Suppl.3):367- 375.
Sutin AR, Zonderman A.B. Depressive symptoms are associated with weight gain among women. Psychol Med 2012; 42:2351-2360.
Pan A, Sun Q, Czernichow S, Kivimaki M, Oke- reke OI, Lucas M, et al. Bidirectional association between depression and obesity in middle-aged and older women. Int J Obes (Lond) 2012; 36(Suppl.4):595-602.